BACKGROUND: Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated. METHODS: T-regulatory cells and Th1/Th17 responses were assessed by flow cytometry and real-time polymerase chain reaction more than 4 years after transplantation in 10 kidney recipients treated with alemtuzumab induction. Seven patients were converted to sirolimus monotherapy at 12 months posttransplant, whereas the remaining three patients with history of graft rejection were treated with sirolimus and mycophenolate mofetil. In addition, we sorted and expanded interleukin (IL)-17A-producing CCR6CD4 T cells and assessed their susceptibility to suppression by regulatory T (Treg) cells in in vitro suppression tests. RESULTS: Three years of mammalian target of rapamycin inhibitor monotherapy correlates with an increase in the number of IL-17A producing cells, compared with patients treated with sirolimus and mycophenolate mofetil. In these patients, IL-17A expression was compensated for by an increase in Treg cell frequency and number. In addition, we demonstrated that both proliferation and cytokine production by Th17 cells can be effectively regulated by Treg cells. CONCLUSIONS: Our results demonstrate that history of rejection and long-term maintenance immunosuppression has an impact on the number of circulating Treg and Th17 cells. However, more importantly, we have shown that Treg cells can effectively regulate Th17cells both in vitro and in vivo.
BACKGROUND: Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated. METHODS: T-regulatory cells and Th1/Th17 responses were assessed by flow cytometry and real-time polymerase chain reaction more than 4 years after transplantation in 10 kidney recipients treated with alemtuzumab induction. Seven patients were converted to sirolimus monotherapy at 12 months posttransplant, whereas the remaining three patients with history of graft rejection were treated with sirolimus and mycophenolate mofetil. In addition, we sorted and expanded interleukin (IL)-17A-producing CCR6CD4 T cells and assessed their susceptibility to suppression by regulatory T (Treg) cells in in vitro suppression tests. RESULTS: Three years of mammalian target of rapamycin inhibitor monotherapy correlates with an increase in the number of IL-17A producing cells, compared with patients treated with sirolimus and mycophenolate mofetil. In these patients, IL-17A expression was compensated for by an increase in Treg cell frequency and number. In addition, we demonstrated that both proliferation and cytokine production by Th17 cells can be effectively regulated by Treg cells. CONCLUSIONS: Our results demonstrate that history of rejection and long-term maintenance immunosuppression has an impact on the number of circulating Treg and Th17 cells. However, more importantly, we have shown that Treg cells can effectively regulate Th17cells both in vitro and in vivo.
Authors: Christopher J E Watson; J Andrew Bradley; Peter J Friend; John Firth; Craig J Taylor; John R Bradley; Kenneth G C Smith; Sathia Thiru; Neville V Jamieson; Geoff Hale; Herman Waldmann; Roy Calne Journal: Am J Transplant Date: 2005-06 Impact factor: 8.086
Authors: B M Vanaudenaerde; L J Dupont; W A Wuyts; E K Verbeken; I Meyts; D M Bullens; E Dilissen; L Luyts; D E Van Raemdonck; G M Verleden Journal: Eur Respir J Date: 2006-04 Impact factor: 16.671
Authors: Sean H Chang; Graeme R Russ; Steven J Chadban; Scott B Campbell; Stephen P McDonald Journal: Transplantation Date: 2007-09-15 Impact factor: 4.939
Authors: Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani Journal: Nat Immunol Date: 2007-05-07 Impact factor: 25.606
Authors: Stuart J Knechtle; John D Pirsch; John H Fechner; Bryan N Becker; Andreas Friedl; Robert B Colvin; Lauralynn K Lebeck; L Thomas Chin; Yolanda T Becker; Jon S Odorico; Anthony M D'Alessandro; Munci Kalayoglu; Majed M Hamawy; Huaizhong Hu; Debra D Bloom; Hans W Sollinger Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Thijs K Hendrikx; Jurjen H L Velthuis; Mariska Klepper; Eveline van Gurp; Annemarie Geel; Wenda Schoordijk; Carla C Baan; Willem Weimar Journal: Transpl Int Date: 2009-05-05 Impact factor: 3.782
Authors: S J Knechtle; J Pascual; D D Bloom; J R Torrealba; E Jankowska-Gan; W J Burlingham; J Kwun; R B Colvin; V Seyfert-Margolis; K Bourcier; H W Sollinger Journal: Am J Transplant Date: 2009-03-16 Impact factor: 8.086
Authors: Xueli Yuan; Jesus Paez-Cortez; Isabela Schmitt-Knosalla; Francesca D'Addio; Bechara Mfarrej; Michela Donnarumma; Antje Habicht; Michael R Clarkson; John Iacomini; Laurie H Glimcher; Mohamed H Sayegh; M Javeed Ansari Journal: J Exp Med Date: 2008-12-01 Impact factor: 14.307
Authors: Pablo J E J van de Berg; Eveline C Hoevenaars; Si-La Yong; Karlijn A M I van Donselaar-van der Pant; Anne van Tellingen; Sandrine Florquin; René A W van Lier; Fréderike J Bemelman; Ineke J M ten Berge Journal: Immunology Date: 2012-06 Impact factor: 7.397
Authors: Lorenzo Gallon; Opas Traitanon; Nedjema Sustento-Reodica; Joseph Leventhal; M Javeed Ansari; Ricardo C Gehrau; Venkatesh Ariyamuthu; Sacha A De Serres; Antonio Alvarado; Darshika Chhabra; James M Mathew; Nader Najafian; Valeria Mas Journal: Kidney Int Date: 2014-10-29 Impact factor: 10.612